Abstract: The methods and uses described herein relate to the modulation of the immune system by modulation of Sema3F levels and/or activity, e.g. suppressing allograft rejection or inflammation by administering a Sema3F agonist or increasing an immune response by administering a Sema3F inhibitor.
Type:
Application
Filed:
April 6, 2023
Publication date:
August 17, 2023
Applicant:
CHILDREN'S MEDICAL CENTER CORPORATION
Inventors:
David M. BRISCOE, Michael KLAGSBRUN, Sarah BRUNEAU, Nora KOCHUPURAKKAL, Hironao NAKAYAMA
Abstract: The present invention features, in some embodiments, compositions comprising ex vivo or in vitro generated functional enteroendocrine (EE) cells, or enteroids, rectoids, or organoids comprising functional enteroendocrine cells, and methods of obtaining and using such cells for treating metabolic and gastrointestinal diseases, disorders, or conditions.
Type:
Application
Filed:
June 16, 2021
Publication date:
August 17, 2023
Applicant:
The Children's Medical Center Corporation
Abstract: A method of detecting triple negative breast cancer (TNBC) is provided. Overexpression of ICAM-1 is linked to an increased risk of TNBC. A composition of matter is also provided that binds an anti-ICAM~1 antibody to a nanoparticle. The composition may be used as an imaging agent and/or a therapeutic targeting agent. A therapeutically active molecule may be bound to the composition to provide targeted therapy.
Type:
Application
Filed:
December 29, 2022
Publication date:
August 10, 2023
Applicant:
Children's Medical Center Corporation
Inventors:
Debra Auguste, Marsha A. Moses, Peng Guo
Abstract: The inventors have developed tools for quantifying the mitochondrial redox state of in vivo, in situ tissue using resonance Raman spectroscopy. The tissue is illuminated with an excitation beam that causes the tissue to scatter Raman-shifted light, which is collected and analyzed to produce coefficients representing the relative concentrations of different chromophores in the tissue. These relative concentrations indicate the redox state of whole mitochondria, hemoglobin oxygen saturation, myoglobin oxygen saturation, and/or redox state of individual cytochrome complexes in mitochondria of the in vivo, in situ tissue. Quantifiable information about these states and/or saturations can be used to assess tissue health, including organ (dys)function before, during, and after surgery. For example, this information can be used to predict impending cardiac failure, to guide surgical interventions, to monitor organ health after transplantation, or to guide post-operative care.
Type:
Grant
Filed:
March 18, 2020
Date of Patent:
August 8, 2023
Assignees:
Pendar Technologies, LLC, Children's Medical Center Corporation
Inventors:
John P. Romfh, Daryoosh Vakhshoori, John N. Kheir, Peili Chen, Brian Polizzotti, Joshua Salvin, Alison Perry
Abstract: A stent assembly for insertion into an airway of a patient includes a stent defining an interior pathway along a length of the stent. The stent assembly includes a removal instrument for removal of the stent from the airway of the patient. The removal instrument is configured to cause a helical motion of the stent to remove the stent from the airway of the patient.
Abstract: Provided herein are products and methods for detecting analytes using polymers that bind to such analytes and thereby undergo a conformational change or contribute to a newly formed complex.
Abstract: The present invention features methods and composition directed to treating neuronal injury, CNS lesion, and/or promoting axon regeneration using a phosphine sulfide-stabilized phosphine.
Type:
Grant
Filed:
September 9, 2020
Date of Patent:
August 1, 2023
Assignees:
CHILDREN'S MEDICAL CENTER CORPORATION, GEORGIA TECH RESEARCH CORPORATION
Inventors:
Elena G. Sergeeva, Paul A. Rosenberg, Larry I. Benowitz, Christoph J. Fahrni, Michael Thomas Morgan
Abstract: Provided herein are nucleic acid molecules that target the BCL11A enhancer functional regions, compositions comprising the nucleic acid molecules and methods for increasing fetal hemoglobin levels in a cell by disrupting BCL11A expression at the genomic level. Also provided herein are methods and compositions relating to the treatment of hemoglobinopathies by reinduction of fetal hemoglobin levels. In particular, the nucleic acid molecules target the +62, +58, and/or the +55 enhancer functional regions.
Type:
Application
Filed:
December 30, 2022
Publication date:
July 27, 2023
Applicants:
The Children's Medical Center Corporation, The Broad Institute, Inc., Massachusetts Institute of Technology
Inventors:
Daniel E. Bauer, Stuat H. Orkin, Neville Sanjana, Ophir Shalem, Feng Zhang
Abstract: Described herein are methods and compositions for treating a coronavirus infectious disease, e.g., COVID-19. Aspects of the invention relate to administering to a subject an agent that targets Notch4.
Type:
Application
Filed:
June 11, 2021
Publication date:
July 20, 2023
Applicant:
The Children's Medical Center Corporation
Inventors:
Talal Chatila, Hani Harb, Mehdi Benamar
Abstract: Embodiments herein relate to in vitro production methods of hematopoietic stem cell (HSC) and hematopoietic stem and progenitor cell (HSPC) that have long-term multilineage hematopoiesis potentials upon in vivo engraftment. The HSC and HSPCs are derived from pluripotent stem cells-derived hemogenic endothelia cells (HE) by non-integrative episomal vectors-based gene transfer.
Type:
Application
Filed:
December 28, 2022
Publication date:
July 20, 2023
Applicant:
THE CHILDREN'S MEDICAL CENTER CORPORATION
Abstract: The present invention relates to the role of purinergic receptors and ATP in T cell activation and autocrine system signaling. In one embodiment, the present invention provides a method of preventing or treating diabetes by administering a therapeutically effective inhibitor of ATP to a subject. In another embodiment, the present invention provides a method of preventing or treating fibrosis by administering a P2X7R soluble fusion protein. In another embodiment, the present invention provides a method of preventing or treating graft rejection by administering an inhibitor of P2X receptor signaling.
Abstract: Provided herein are methods of treating neurodevelopmental disorders, including the treatment of Tuberous sclerosis complex (TSC), with pharmaceutical compositions containing heat shock protein (Hsp) inhibitors and/or mTOR inhibitors. Also provided herein are methods for inhibiting mechanistic target of rapamycin complex 1 (mTORC1) activity and/or increasing or normalizing ciliation.
Type:
Application
Filed:
June 8, 2021
Publication date:
July 13, 2023
Applicant:
The Children's Medical Center Corporation
Abstract: The present disclosure provides compounds of Formula (I). The compounds described herein may be useful in treating and/or preventing proliferative diseases (e.g., cancer). Also provided in the present disclosure are pharmaceutical compositions, kits, methods, and uses including or using a compound described herein.
Type:
Grant
Filed:
May 4, 2021
Date of Patent:
July 11, 2023
Assignees:
Children's Medical Center Corporation, Beth Israel Deaconess Medical Center, Inc.
Abstract: This disclosure relates to methods of determining the amount of post translational modification (PTM) associated with one or more tau peptide fragments of a tau protein in a sample, and methods of evaluating a subject for having a tauopathy, the methods comprising, in part, determining the amount of post translational modification (PTM) associated with one or more tau peptide fragments of a tau protein in a sample, and comparing the amount of the tau PTMs associated with one or more tau peptide fragments with one or more reference levels for the tau peptide fragments, thereby determining whether a subject has a tauopathy.
Type:
Grant
Filed:
September 23, 2016
Date of Patent:
July 11, 2023
Assignee:
Children's Medical Center Corporation
Inventors:
Judith AJ Steen, Hanno Steen, Waltraud Mair, Jan Muntel, Shaojun Tang
Abstract: The invention described herein is directed to compositions and methods for inducing red blood cell (RBC) differentiation. Additionally, provided herein are methods of treating a subject in need thereof by administering the induced RBC described herein.
Type:
Application
Filed:
June 17, 2021
Publication date:
July 6, 2023
Applicant:
The Children's Medical Center Corporation
Inventors:
Ashlee J. Conway, Tolulope O. Rosanwo, Thomas E. Williamson, Trista E. North, George Q. Daley
Abstract: An implantable, autonomously growing medical device is disclosed. The device may have an outer, braided outer element that holds an inner core. Degradation and/or softening of the inner core permits the outer element to elongate, allowing the device to grow with surrounding tissue. The growth profile of the medical device can be controlled by altering the shape/material/cure conditions of the inner core, as well as the geometry of the out element.
Type:
Application
Filed:
September 1, 2022
Publication date:
July 6, 2023
Applicants:
Children's Medical Center Corporation, The Brigham and Women's Hospital, Inc.
Inventors:
Eric N. Feins, Pedro J. del Nido, Nikolay V. Vasilyev, Haruo Yamauchi, Douglas P. Perrin, Peter E. Hammer, Veaceslav Arabagi, Jeffrey M. Karp, Yuhan Lee, Eoin D. O'Cearbhaill
Abstract: Provided herein, in some aspects, are compositions and methods for treating Barth syndrome (BTHS) using human tafazzin gene therapy or enzyme replacement therapy. The present disclosure, in some aspects, provides compositions and methods (e.g., gene therapy or enzyme replacement therapy) for treating Barth syndrome (BTHS). It was demonstrated herein that certain human Tafazzin (hTAZ) isoforms and the full length protein, as well as nucleic acids encoding them, are effective in treating BTHS.
Abstract: Described herein are methods and compositions for treating asthma or an allergic disease. Aspects of the invention relate to administering to a subject an agent that targets the Wnt or Hippo Signaling pathway, or Growth-differentiation factor 15 (GDF15), either alone or in combination. In certain embodiments, the subject is further administered a Notch4 inhibitor.
Type:
Application
Filed:
February 16, 2021
Publication date:
July 6, 2023
Applicant:
THE CHILDREN'S MEDICAL CENTER CORPORATION
Abstract: Provided herein are adjuvantation systems for use in Beta coronavirus (e.g., MERS-CoV, SARS-CoV-1, or SARS-CoV-2) vaccines and immunogenic compositions comprising the adjuvantation system and a Beta coronavirus antigen.
Type:
Application
Filed:
May 28, 2021
Publication date:
June 29, 2023
Applicant:
Children's Medical Center Corporation
Inventors:
David J. Dowling, Ofer Levy, Francesco Borriello, Etsuro Nanishi, Timothy O'Meara, Yoshine Saito, Simon D. van Haren